A groundbreaking study published in Nature has unveiled a new therapeutic avenue for combating one of the most elusive and treatment-resistant forms of prostate cancer. Researchers have identified that targeting the epigenetic regulator NSD2 can reverse the drug resistance characteristic of neuroendocrine prostate cancer (CRPC-NE), restoring sensitivity to the widely-used androgen receptor (AR) inhibitor enzalutamide. This discovery promises to reshape the treatment landscape for patients suffering from advanced prostate malignancies, notoriously difficult to manage due to their inherent plasticity and adaptive mechanisms.
The challenge in treating CRPC-NE lies in its aggressive nature and diminished dependence on androgen receptor signaling—a pathway conventional therapies target. Tumors frequently circumvent AR blockade by adopting neuroendocrine phenotypes, which no longer respond to AR inhibitors like enzalutamide, leading to poor clinical outcomes. Through sophisticated genetic manipulation of patient-derived organoid models, the research team demonstrated that ablating NSD2 reactivates AR expression and reinstitutes tumor vulnerability to enzalutamide, offering a novel method to overcome therapeutic resistance.
In an extensive series of experiments, NSD2 was inactivated via CRISPR-Cas9 mediated gene knockout in neuroendocrine prostate cancer organoids. Remarkably, this intervention reinstated AR protein levels that had previously been downregulated in CRPC-NE states. Employing dose–response assays, the investigators observed a significant reduction in organoid growth upon treatment with enzalutamide post-NSD2 targeting, with half-maximal inhibitory concentrations (IC50) plummeting below 3 micromolar. This quantitative shift underscored a dramatic re-sensitization of cancer cells to androgen deprivation therapies.
Extending these findings to in vivo models, the team employed subcutaneous grafting of both NSD2-deficient and control organoids into immunodeficient NOD/SCID mice. Upon reaching a critical tumor size, animals were treated with enzalutamide or vehicle control. Tumors lacking NSD2 exhibited significantly impaired growth under androgen blockade, while controls continued to proliferate unabated. Histological examination revealed a profound phenotypic switch; loss of neuroendocrine markers coupled with decreased proliferation indices such as Ki67 and resurgence of adenocarcinoma characteristics highlighted epigenetic reversion towards a more canonical prostate cancer state.
Parallel experiments utilizing human-derived MSKPCa10 organoids substantiated the translational relevance of these findings. NSD2 knockout in these human cells similarly restored responsiveness to enzalutamide both in vitro and in xenograft models, suggesting a conserved mechanism linking NSD2 activity to drug resistance across species. This critical validation establishes NSD2 as a viable target for clinical intervention in therapy-refractory prostate cancers.
Mechanistic insights at the molecular level revealed that NSD2 depletion triggers a global reprogramming of androgen receptor signaling. The expression of classical AR target genes showed robust enrichment post-NSD2 targeting, an effect confirmed at single-cell resolution. Notably, NSD2-deficient organoids manifested a proliferative response to the AR agonist dihydrotestosterone (DHT), which was absent in controls—indicating a restoration of functional AR signaling capable of modulating tumor cell growth.
This study situates NSD2 as a central epigenetic effector that governs phenotypic plasticity in prostate cancer, facilitating the shift from AR-dependent adenocarcinoma to neuroendocrine phenotypes upon which standard therapies fail. By reversing this epigenetic switch, NSD2 inhibition reinstates the canonical AR transcriptional program, reversing resistance and sensitizing tumors to enzalutamide. These findings unlock new paths for targeted epigenetic therapy, potentially combining NSD2 inhibitors with existing AR antagonists to overcome resistance mechanisms.
Furthermore, the work highlights the utility of patient-derived organoids as powerful preclinical platforms enabling precise genetic editing and pharmacological testing. This approach allows real-time evaluation of molecular dependencies within heterogeneous cancer cell populations, accelerating the discovery of context-specific vulnerabilities. The successful translation of organoid-based results into in vivo murine models strengthens the potential for rapid clinical application.
Overall, this paradigm-changing research advances our understanding of molecular determinants underpinning prostate cancer evolution and therapy resistance. It underscores the intricate interplay between epigenetic modifiers and hormonal signaling pathways, offering hope for more durable and effective interventions against metastatic prostate cancer. With further development, NSD2 targeting could usher in a new era of precision epigenetic therapies complementing androgen receptor blockade.
The promising results prompt urgent exploration into the development of selective NSD2 inhibitors suitable for clinical use. Future investigations will be crucial to unravel potential off-target effects, establish optimal dosing regimens, and assess therapeutic windows when combined with enzalutamide. Given the dire prognosis associated with CRPC-NE, this line of research may significantly extend survival and improve quality of life for affected patients.
In light of these discoveries, integrating epigenetic modulation strategies into standard prostate cancer treatment algorithms appears an auspicious direction. The elucidation of resistance reversal mechanisms by NSD2 loss provides a conceptual blueprint for tackling the heterogeneity and adaptability that have so far confounded durable responses in late-stage disease. As research progresses, the prospect of overcoming the deadliest phenotypes of prostate cancer moves closer to reality.
These breakthroughs also raise compelling questions about the broader role of epigenetic regulators in cancer plasticity and drug resistance beyond prostate cancer. By exploiting similar vulnerabilities in other malignancies exhibiting lineage plasticity, targeted NSD2 inhibition or analogous epigenetic reprogramming might enhance responsiveness to a variety of existing therapies. This study therefore opens avenues of translational potential across oncology.
In conclusion, the identification of NSD2 as a pivotal regulator of therapeutic plasticity and resistance in neuroendocrine prostate cancer represents a milestone in cancer epigenetics and precision medicine. The restoration of enzalutamide sensitivity via NSD2 targeting reveals actionable vulnerabilities that can be leveraged to design revolutionary treatment combinations. This paradigm shift affords renewed hope for patients battling drug-resistant prostate cancer and exemplifies the power of integrating genetic and epigenetic insights to surmount clinical challenges.
Subject of Research: Epigenetic regulation and therapeutic resistance in neuroendocrine prostate cancer
Article Title: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
Article References:
Li, J.J., Vasciaveo, A., Karagiannis, D. et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09727-z
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-025-09727-z
Tags: advanced prostate malignancies managementandrogen receptor signaling blockadeCRISPR-Cas9 gene editing in oncologyCRPC-NE epigenetic regulationenzalutamide sensitivity restorationneuroendocrine prostate cancer researchpatient-derived organoid models in cancerprostate cancer treatment resistancereversing drug resistance in cancer therapiestargeting NSD2 in cancer therapytherapeutic strategies for aggressive prostate cancertumor plasticity and adaptive mechanisms
